Technology
Health
Pharmaceutical

Adamis Pharmaceuticals

$2.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-2.59%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADMP and other stocks, options, ETFs, and crypto commission-free!

About

Adamis Pharmaceuticals Corporation Common Stock, also called Adamis Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. Read More The company was founded in June 2006 and is headquartered in San Diego, CA.

Employees
152
Headquarters
San Diego, California
Founded
2006
Market Cap
109.72M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
628.89K
High Today
$2.32
Low Today
$2.19
Open Price
$2.32
Volume
238.37K
52 Week High
$5.10
52 Week Low
$2.01

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
US
North America

News

Seeking Alpha16h

Adamis Pharmaceuticals: Refused, Accepted, Missed, And Predictable

The company released a positive press release about the milestone achieved in 2018, but a thorough reading of the 10-K was required to find out that the company is in a legal battle with Belcher Pharmaceuticals over an epinephrine patent.

188
MarketWatchMar 19

Adamis Pharmaceuticals Corp.

Adamis Pharmaceuticals Corp. shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the ...

386
Markets InsiderMar 14

Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration ("FDA”) has accepted for review the company’s New Drug Application ("NDA”) for its higher naloxone injection product candidate for the treatment of opioid overdose.

711

Earnings

-$0.29
-$0.24
-$0.18
-$0.13
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.19 per share
Actual
-$0.28 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.